Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Heart (British Cardiac Society)
|
November 29, 2014
Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension
Melvin D Lobo, Mark A de Belder, Trevor Cleveland, et al.
The American Journal of Cardiology
|
September 2, 2021
Relation of High-Sensitivity Troponin to 1 Year Mortality in 20,000 Consecutive Hospital Patients Undergoing a Blood Test for Any Reason
Jonathan Hinton, Mark Mariathas, Lavinia Gabara, et al.
Journal of Medicinal Chemistry
|
November 14, 2024
Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors
Jason D Shields, Brian M Aquila, David Emmons, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 30, 2020
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase
Sameer P Kawatkar, Bernard Barlaam, Paul Kemmitt, et al.
ACS Chemical Biology
|
November 14, 2017
Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily
Jonathan D Wrigley, Gerald Gavory, Iain Simpson, et al.
Journal of Medicinal Chemistry
|
November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
Scott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry
|
December 23, 2016
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells
Stuart Jones, Jonathan Ahmet, Kelly Ayton, et al.
Journal of Medicinal Chemistry
|
April 5, 2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point
Richard A Ward, Paul Bethel, Calum Cook, et al.
Molecular Cancer Therapeutics
|
March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
Aatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Molecular Cancer Therapeutics
|
December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Vikki Flemington, Emma J Davies, David Robinson, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Heart (British Cardiac Society)
|
November 29, 2014
Joint UK societies' 2014 consensus statement on renal denervation for resistant hypertension
Melvin D Lobo, Mark A de Belder, Trevor Cleveland, et al.
The American Journal of Cardiology
|
September 2, 2021
Relation of High-Sensitivity Troponin to 1 Year Mortality in 20,000 Consecutive Hospital Patients Undergoing a Blood Test for Any Reason
Jonathan Hinton, Mark Mariathas, Lavinia Gabara, et al.
Journal of Medicinal Chemistry
|
November 14, 2024
Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors
Jason D Shields, Brian M Aquila, David Emmons, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 30, 2020
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase
Sameer P Kawatkar, Bernard Barlaam, Paul Kemmitt, et al.
ACS Chemical Biology
|
November 14, 2017
Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily
Jonathan D Wrigley, Gerald Gavory, Iain Simpson, et al.
Journal of Medicinal Chemistry
|
November 22, 2024
Discovery of (2<i>R</i>,4<i>R</i>)-4-((<i>S</i>)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer
Scott N Mlynarski, Brian M Aquila, Susan Cantin, et al.
Journal of Medicinal Chemistry
|
December 23, 2016
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells
Stuart Jones, Jonathan Ahmet, Kelly Ayton, et al.
Journal of Medicinal Chemistry
|
April 5, 2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point
Richard A Ward, Paul Bethel, Calum Cook, et al.
Molecular Cancer Therapeutics
|
March 13, 2023
Novel Arginase Inhibitor, AZD0011, Demonstrates Immune Cell Stimulation and Antitumor Efficacy with Diverse Combination Partners
Aatman S Doshi, Susan Cantin, Marylens Hernandez, et al.
Molecular Cancer Therapeutics
|
December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Vikki Flemington, Emma J Davies, David Robinson, et al.
Page
of 5